

We Claim:

1. A composition comprising at least two siRNA duplexes and a pharmaceutically effective carrier wherein each of said siRNA duplexes inhibits expression of a gene associated with a disease process.
2. The composition according to Claim 1 wherein said genes are distinct genes.
3. The composition according to Claim 1 wherein said composition comprises at least three siRNA duplexes.
4. The composition according to Claim 1 wherein said siRNA duplexes inhibit expression of at least three gene sequences including three open reading frames and three mRNAs.
5. The composition according to claim 1 wherein said genes are endogenous human genes.
6. The composition according to claim 1 wherein said genes are exogenous genes of one or more pathogens.
7. The composition according to claim 1 wherein said siRNA duplexes are chemically synthetic forms, comprising naturally occurring RNA bases and/or chemically modified RNA bases of RNA base analogs.
8. A method of treating a disease in a subject, comprising administering to said subject a composition according to claim 1.
9. A method of target validation comprising administering a composition according to claim 1 to a test subject and measuring changes in gene expression in said subject.
10. The method according to claim 8 wherein said composition is administered via local injection, inhalation, topical cream, dermal patch, or systemic delivery by IV, IP or IM injection.
11. The composition according to claim 1 comprising aagtcctaattacactcaac; aaggatgaggaaggcaattta; aaggataagtcagctcaatgc; and aactggcacactactgtcga.
12. A method of treating a coronavirus in a subject comprising administering to said subject a composition according to claim 1.
13. The composition according to claim 1 comprising AAGCCGTCCTGTGTGCCGCTG; AACGATGAAGCCCTGGAGTGC;

AAGTTAAAAGTGCCTGAACTG; AAGCAGGCCAGACTCTCTTTC;
AAGCTCAGCACACAGAAAGAC; and AATGCGGCGGTGGTGACAGTA.

14. A method of treating ocular disease in a subject comprising administering to said subject a composition according to claim 13.

15. A composition comprising a combination of siRNA duplexes that inhibit expression of VEGF, VEGF R2 and VEGF R1, wherein said duplexes are selected from Figure 17.

16. The method according to claim 8 wherein said disease is selected from the group consisting of ocular neovascularization diseases such as wet AMD, diabetic retinopathy and stromal keratitis, various types of cancers, rheumatoid arthritis and lung angiogenesis disease.

17. The method according to claim 8 wherein said disease is selected from the group consisting of cancer, autoimmune and inflammatory diseases, and other diseases caused or exacerbated by abnormal over expression of multiple genes.

18. The composition according to claim 1 wherein said siRNA duplexes target mRNA sequences of VEGF, VEGF R1 and VEGF R2 and are selected from Figure 17 SS1, SS2 and SS3.

19. A method of treating an angiogenesis-related disease comprising administering a composition according to claim 18, wherein said disease is cancer, ocular neovascularization, such as wet AMD, diabetic retinopathy, peripheral retinal neovascularization, or glaucoma.

20. The composition according to claim 1 wherein said siRNA duplexes target mRNA sequences of EGF receptor, VEGF and FGF, and are selected from Figure 17 SS1, SS2 and SS3.

21. The composition according to claim 1 wherein said siRNA duplexes target mRNA sequences of EGF receptor, VEGF receptor and FGF receptor, and are selected from Figure 17 SS1, SS2 and SS3.

22. A method of treating cancer in a subject comprising administering to said subject a composition according to claim 20 or 21

23. The composition according to claim 1 wherein said siRNA duplexes target mRNA sequences of androgen receptor, VEGF and AMACR, and are selected from Figure 17 SS2 and SS53.

24. A method of treating prostate cancer in a subject comprising administering to said subject a composition according to claim 23.

25. The composition according to claim 1 wherein said siRNA duplexes target mRNA sequences of VEGF, c-Met and PCDP10, and are selected from Figure 17 SS2, SS4 and SS5.

26. A method of treating liver, lung or colon cancer in a subject comprising administering to said subject a composition according to claim 25.

27. The composition according to claim 1 wherein said siRNA duplexes target mRNA sequences of HGF, c-Met and VEGF, and are selected from Figure 17 SS2, SS3.

28. A method of treating liver cancer in a subject comprising administering to said subject a composition according to claim 27.

29. The composition according to claim 1 wherein said siRNA duplexes target mRNA sequences of EGF receptor, VEGF and p53 mutants, and are selected from Figure 17 SS1, SS2 and SS3.

30. A method of treating lung cancer in a subject comprising administering to said subject a composition according to claim 29.

31. The composition according to claim 1 wherein said siRNA duplexes target mRNA sequences of HPV16 and HPV18's E6, E7 and human p53 mutants.

32. A method of treating cervical cancer in a subject comprising administering to said subject a composition according to claim 31.

33. The composition according to claim 1 wherein said siRNA duplexes target mRNA sequences of MMP-2, PDGF-R and $\alpha\beta 3$ integrin.

34. A method of treating cancer in a subject comprising administering to said subject a composition according to claim 33.

35. The composition according to claim 1 wherein said siRNA duplexes target mRNA sequences of TNF alpha, IL-1 and IL-1 receptor.

36. A method of treating an inflammatory disease in a subject comprising administering to said subject a composition according to claim 35.

37. The method according to claim 36 wherein said disease is rheumatoid arthritis, uveitis, psoriasis or Crohn's disease.

39. The composition according to claim 1 wherein said siRNA duplexes target mRNA sequences of IL-9, IL-4 and IL-5.

40. A method of treating asthma, pulmonary fibrosis or ARDS in a subject comprising administering to said subject a composition according to claim 39.

41. The composition according to claim 1 wherein said siRNA duplexes target mRNA sequences of viral nucleocapsid protein, nonglycosylated inner virion protein and a transmembrane glycoprotein (F) of RSV virus, and are selected from Figure 17, SS6.

42. A method of treating a subject suffering from an RSV infection comprising administering to said subject a composition according to claim 41.

43. The composition according to claim 1 wherein said siRNA duplexes target mRNA sequences of Spike protein, RNA polymerase and RNA replicase of SARS-CoV, and are selected from Figure 17 SS7.

44. A method of treating SARS in a subject comprising administering to said subject a composition according to claim 43.